{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:15:54Z","timestamp":1790741754130,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["KL2 RR024983"],"award-info":[{"award-number":["KL2 RR024983"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cardfail.2026.05.016","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:59:20Z","timestamp":1781798360000},"page":"1475-1481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["What Are Heart Failure With Preserved Ejection Fraction Mimics and What Are They Mimicking? Insights Into Our Conceptualization of Heart Failure With Preserved Ejection Fraction as a Disease"],"prefix":"10.1016","volume":"32","author":[{"given":"MILTON","family":"PACKER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JAVED","family":"BUTLER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JENNIFER E.","family":"HO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CAROLYN S.P.","family":"LAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARK C.","family":"PETRIE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GABRIELE G.","family":"SCHIATTARELLA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MUTHIAH","family":"VADUGANATHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FAIEZ","family":"ZANNAD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BARRY A.","family":"BORLAUG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.05.016_bib0001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0002","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcmg.2018.12.034","article-title":"Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods","volume":"13","author":"Obokata","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0003","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0004","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jchf.2023.03.011","article-title":"How to manage heart failure with preserved ejection fraction: practical guidance for clinicians","volume":"11","author":"Desai","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0005","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0002-9149(84)80207-6","article-title":"Congestive heart failure with normal systolic function","volume":"54","author":"Dougherty","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0006","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1532-5415.1982.tb01983.x","article-title":"Left ventricular function in hospitalized geriatric patients","volume":"30","author":"Luchi","year":"1982","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0007","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM198501313120504","article-title":"Hypertensive hypertrophic cardiomyopathy of the elderly","volume":"312","author":"Topol","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0008","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0735-1097(95)00503-X","article-title":"Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT)","volume":"27","author":"Carson","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0009","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/ejhf.1160","article-title":"Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction","volume":"20","author":"Abdul-Rahim","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0010","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0011","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0012","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0013","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0014","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0016","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0017","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0018","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0019","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0020","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/jama.2018.14852","article-title":"Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial","volume":"320","author":"Borlaug","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0021","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1001\/jamacardio.2024.4417","article-title":"Potassium nitrate in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"10","author":"Zamani","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0022","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/jama.2020.16641","article-title":"Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial","volume":"324","author":"Udelson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0023","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0024","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","article-title":"Isosorbide mononitrate in heart failure with preserved ejection fraction","volume":"373","author":"Redfield","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0025","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial","volume":"43","author":"Dachs","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0026","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0027","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1038\/s41591-025-03939-6","article-title":"Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102714","article-title":"Rationale and design of the HeartShare\/AMP-HF deep phenotyping study to improve understanding of heart failure with preserved ejection fraction","volume":"13","author":"Borlaug","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0029","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0031","unstructured":"Rossano JW, Canter C, Wolf CM, Papez A, Gambra M, Bryant RM, et al; SCOUT-HCM Investigators. Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy. N Engl J Med, in press."},{"key":"10.1016\/j.cardfail.2026.05.016_bib0032","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133273","article-title":"Long term prognosis in cardiac sarcoidosis under FDG-PET guided immunosuppressive therapy","volume":"432","author":"Imamura","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0034","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cardfail.2010.05.009","article-title":"Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment","volume":"16","author":"Murphy","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pcad.2025.08.003","article-title":"Fabry disease cardiomyopathy: a state-of-the-art review","volume":"92","author":"Pande","year":"2025","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1223635","article-title":"Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease","volume":"10","author":"Pogoda","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0037","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41430-023-01279-7","article-title":"Thiamine responsive high output heart failure of adults: an under-recognized entity","volume":"77","author":"Nisar","year":"2023","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0038","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1177\/11297298241287946","article-title":"The management of high flow arteriovenous fistula and possible solutions","volume":"26","author":"Cristiano","year":"2025","journal-title":"J Vasc Access"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0039","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1007\/s00330-022-08621-w","article-title":"Time-dependent cardiac structural and functional changes after kidney transplantation: a multi-parametric cardiac magnetic resonance study","volume":"32","author":"Qi","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0040","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001647","article-title":"Left ventricular hypertrophy after renal transplantation: systematic review and meta-analysis","volume":"10","author":"Tian","year":"2024","journal-title":"Transplant Direct"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0041","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jcmg.2022.05.009","article-title":"Transcatheter mitral valve repair in patients with atrial functional mitral regurgitation","volume":"15","author":"Doldi","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0042","article-title":"A near-miss event: constrictive pericarditis misdiagnosed as heart failure with preserved ejection fraction","volume":"17","author":"Rayamajhi","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0043","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0044","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12916-021-02219-7","article-title":"Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.amjcard.2023.07.175","article-title":"Revascularization for patients with heart failure with preserved ejection fraction and coronary artery disease","volume":"213","author":"Fu","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0046","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"46","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0047","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2025.08.012","article-title":"Adiposity-related anthropometrics and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: a participant-level pooled analysis of randomized clinical trials","volume":"86","author":"Ostrominski","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0048","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ejhf.2403","article-title":"Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction","volume":"24","author":"Jackson","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0049","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2025.03.530","article-title":"Disentangling the impact of adiposity from insulin resistance in heart failure with preserved ejection fraction","volume":"85","author":"Reddy","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102638","article-title":"What causes inflammation in heart failure with a preserved ejection fraction? Potential role of eicosanoid adipokines","volume":"13","author":"Packer","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0051","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.125.014031","article-title":"What exactly is cardiometabolic HFpEF: a phenotype or an endotype?","volume":"19","author":"Packer","year":"2026","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0052","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0053","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2025.08.036","article-title":"Central adiposity or hypertension: which drives heart failure with a preserved ejection fraction?","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2026.103046","article-title":"Excess and dysfunctional fat as a primary driver of heart failure with preserved ejection fraction: from institutional recognition to clinical integration","volume":"14","author":"Packer","year":"2026","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0055","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.124.072156","article-title":"Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory outpatient setting","volume":"151","author":"Reddy","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0056","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/CIRCULATIONAHA.121.058592","article-title":"Longitudinal evolution of cardiac dysfunction in heart failure and preserved ejection fraction with normal natriuretic peptide levels","volume":"146","author":"Sorimachi","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0057","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jacc.2025.11.024","article-title":"Echocardiographic diastolic function grading in HFpEF: testing the updated 2025 ASE criteria","volume":"87","author":"Harada","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0058","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacc.2024.10.111","article-title":"Finerenone, obesity, and heart failure with mildly reduced\/preserved ejection fraction: prespecified analysis of FINEARTS-HF","volume":"85","author":"Butt","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0059","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/ejhf.2831","article-title":"Health status across major subgroups of patients with heart failure and preserved ejection fraction","volume":"25","author":"Siddiqi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.05.016_bib0060","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jacc.2025.04.059","article-title":"Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: the SUMMIT trial","volume":"86","author":"Borlaug","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426003027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426003027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:28:53Z","timestamp":1786436933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916426003027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1071916426003027"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.05.016","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Are Heart Failure With Preserved Ejection Fraction Mimics and What Are They Mimicking? Insights Into Our Conceptualization of Heart Failure With Preserved Ejection Fraction as a Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}